But when your peripheral nerves-those found outside of the brain and spinal cord-are damaged, it can cause pain and numbness ...

000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

If approved by the EC, Wainzua would be the only approved medicine for the treatment of ATTRv-PN in the EU able to be self-administered with an autoinjector on a monthly basis. “Due to the progressive ...

000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

Having additional amyloidosis treatment options designed to reduce the production of TTR protein at its ... Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca, said: ...

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...

You can learn more about Asuta Health online at asutahealth.org or call 515-218-9500. Asuta Health is located at 210 NE Delaware Avenue in Ankeny. Segment is sponsored by Asuta Health.